Biosimilar nomenclature: Deadline August 2 for comments on FDA’s OMB information request

Meaningful suffix may be in for U.S. biologics, biosimilars

 

 

FDA Pushes Back Comment Period for Biosimilar Labeling

Just released: new deadline August?2 for information collection request it submitted to the White House Office of Management and Budget (OMB)

 

 

Additional Reading

FDA approves Inflectra, a biosimilar to Remicade

A Rocky Start for Biosimilar Inflectra?

FDA Approves INFLECTRA? (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States

FDA Information on Biosimilars

Biosimilar switching not suitable for all patients

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: